Xeris Biopharma Holdings
XERS· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +131.6% in FY2025
John Shannon is the CEO of Xeris Biopharma Holdings and was paid $5.0M in FY2025 (Dec).
Pay$100 in the stock at the end of FY20 → $63
Executives5
See all- 1John ShannonChief Executive OfficerFY2025
- 2Kevin McCullochPresident and Chief Operating OfficerFY2025
- 3Anh NguyenChief Medical OfficerFY2025
- 4Beth P. HechtChief Legal Officer and Corporate SecretaryFY2025
- 5Steven M. PieperChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allXeris Biopharma Holdings paid its 5 named executives $13.1M in total in FY2025 (Dec). CEO John Shannon was paid $5.0M of that.
| Name | |||
|---|---|---|---|
| John ShannonChief Executive Officer | |||
| Kevin McCullochPresident and Chief Operating Officer | Not disclosed | Not disclosed | |
| Anh NguyenChief Medical Officer | Not disclosed | Not disclosed | |
| Beth P. HechtChief Legal Officer and Corporate Secretary | |||
| Steven M. PieperChief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers16
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Jeffrey W. ShermanDirector · 3 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 2, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Mar 6, 2024 | FY2023 |